<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00732875</url>
  </required_header>
  <id_info>
    <org_study_id>P05645</org_study_id>
    <nct_id>NCT00732875</nct_id>
  </id_info>
  <brief_title>A Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methorexate (Extension Part)(Study P05645)(COMPLETED)</brief_title>
  <official_title>A Placebo-controlled, Double-blinded, Randomized Clinical Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methotrexate Treatment (Open-label Extension Part)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is extension part of the P04280 (placebo-controlled, double-blind, randomized
      study of chronic treatment with infliximab in approximately 140 patients, NCT00202852). This
      study will be conducted at 6 study centers in South Korea. After completion of the last
      follow-up visit at Week 30 and code break in main double-blind trial, subjects randomized to
      the placebo group and those who were treated with an infliximab-containing regimen who
      maintained clinical response at the time of study completion will be provided with open-label
      infliximab for treatment of their conditions and additional safety data will be collected.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Experiencing Any Adverse Event</measure>
    <time_frame>throughout entire study (61 +/- 28.9 weeks on average)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Experiencing Serious Adverse Event</measure>
    <time_frame>throughout entire study (61 +/- 28.9 weeks on average)</time_frame>
    <description>Serious adverse events are defined as death, life-threatening events, persistent or significant disability/incapacity, hospitalization or prolongation of hospitalization and congenital anomalies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Experiencing Any Infection</measure>
    <time_frame>throughout entire study (61 +/- 28.9 weeks on average)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>Open Label Infliximab + Methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label Infliximab infusions at weeks 0, 2, and 6 and every 8 weeks + methotrexate (MTX)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infliximab + methotrexate (MTX)</intervention_name>
    <description>Open label Infliximab infusions at weeks 0, 2, and 6 and every 8 weeks + methotrexate (MTX)</description>
    <arm_group_label>Open Label Infliximab + Methotrexate</arm_group_label>
    <other_name>Remicade</other_name>
    <other_name>SCH 215596</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients received placebo in main double-blind study (P04280, NCT00202852)

          -  Patients received Infliximab-containing regimen showing clinical response at week 30
             in main double-blind study (P04280)

        [Main double-blind study (P04280, NCT00202852) inclusion criteria]

          -  Diagnosis of rheumatoid arthritis (RA) according to the revised 1987 criteria of the
             American Rheumatism Association (Arnett et al, 1988). The disease should have been
             diagnosed &gt;6 months prior to screening.

          -  Active disease at the time of screening and pre-infusion as defined by:

               -  &gt;=6 swollen joints

               -  &gt;=6 tender joints and

          -  2 of the following:

               -  morning stiffness &gt;=45 min

               -  erythrocyte sedimentation rate (ESR) &gt;=28 mm/h

               -  C-reactive protein (CRP) &gt;=20 mg/L

          -  Men and women, &gt;=18 to &lt;=75 years of age

          -  Men and women of childbearing potential must be using adequate birth control measures
             (abstinence, oral contraceptives, intrauterine device (IUD), barrier method with
             spermicide, or surgical sterilization) and should continue such precautions for 6
             months after receiving the last infusion.

          -  Must have been using oral or parenteral MTX for &gt;3 months with no break(s) in
             treatment of &gt;2 weeks total during this period. Patients must have been on a stable
             dose of &gt;=12.5 mg/wk (maximum 20 mg/wk) for at &gt;4 weeks prior to screening.

          -  Must be on a stable dose of folic acid prophylaxis for &gt;4 weeks prior to screening.

          -  Patients using oral corticosteroids, must have been on a stable dose of &lt;=10 mg/day
             for &gt;4 weeks prior to screening. If currently not using corticosteroids the patient
             must have not received corticosteroids for &gt;4 weeks prior to screening.

          -  If using nonsteroidal anti-inflammatory drugs (NSAIDs), patients should have been on a
             stable dose for &gt;4 weeks prior to screening.

          -  The screening laboratory tests must meet the following criteria:

               -  Hemoglobin &gt;=5.3 mmol/L (&gt;=8.5 g/dL), providing a low hemoglobin level is not due
                  to nutritional deficiencies or due to diseases other than chronic RA

               -  white blood cell (WBC) &gt;=3.5 x 10^9/L (&gt;=3.5 x 10^3/mm^3)

               -  Neutrophils &gt;=1.5 x 10^9/L (&gt;=1.5 x 103/mm^3)

               -  Platelets &gt;=100 x 10^9/L (&gt;=100 x 103/mm^3)

               -  Serum transaminase &lt;=2 times the upper limit of normal

               -  Alkaline phosphatase levels &lt;=2 times the upper limit of normal

               -  Serum creatinine &lt;=150 Âµmol/L (&lt;=1.7 mg/dL)

          -  Must be able to adhere to the study visit schedule and other protocol requirements.

          -  Must be capable of giving informed consent and the consent must have been obtained
             prior to any study procedures including wash-out period.

        Exclusion Criteria:

          -  Exclusion criteria below of main double-blind study (P04280, NCT00202852)

        [Main double-blind study (P04280, NCT00202852) exclusion criteria]

          -  Pregnant women, nursing mothers, or a planned pregnancy within 1.5 years of
             enrollment.

          -  Patients who are incapacitated, largely or wholly bedridden or confined to a
             wheelchair, and who have little or no ability for self-care.

          -  Patients who have any current systemic inflammatory condition with signs and symptoms
             that might confound the evaluations of benefit from infliximab, eg Lyme disease, or a
             rheumatic disease other than RA.

          -  Use of disease modifying anti-rheumatic drugs (DMARDs) other than MTX within 4 weeks
             prior to screening. (If a patient had prior exposure to leflunomide within the past 6
             months, cholestyramine 8 g should be given 3 times daily for 11 days to rapidly lower
             the plasma level of leflunomide.)

          -  Use of intra-articular, i.m. or i.v. corticosteroids (including i.m. ACTH) within 4
             weeks prior to screening.

          -  Have been previously treated with infliximab or genetic recombinant therapy with RA
             (e.g. etanercept, adalimumab)

          -  Treatment with any other therapeutic agent targeted at reducing TNF (eg,
             pentoxifylline or thalidomide) within the previous 3 months.

          -  Treatment with any investigational drug within the previous 3 months.

          -  Prior use of cyclophosphamide, nitrogen mustard, chlorambucil, or other alkylating
             agents.

          -  History of any clinically significant adverse reaction to murine or chimeric proteins,
             including but not limited to allergic reactions.

          -  History of infected joint prosthesis within previous 5 years.

          -  Serious infections, such as hepatitis, pneumonia, pyelonephritis in the previous 3
             months.

          -  Chronic infectious disease such as chronic renal infection, chronic chest infection
             with bronchiectasis or sinusitis.

          -  Active tuberculosis (TB). Also excluded are patients who have evidence of latent TB
             (positive purified protein derivative [PPD] skin test or a history of latent TB)
             without adequate therapy for TB initiated prior to first infusion of study drug. Also
             excluded are patients with evidence of an old or latent TB infection without
             documented adequate therapy, if they will not be treated with antitubercular therapy
             during the trial. Patients with a current close contact with an individual with active
             TB will also be excluded. Additionally, patients who have completed treatment for
             active TB within the previous 2 years are now explicitly excluded from the trial.
             Patients with a household member who has a history of active pulmonary TB should have
             had a thorough evaluation for TB prior to study enrollment as recommended by a local
             infectious disease specialist or published local guidelines of TB control agencies.
             Also excluded are patients with opportunistic infections, including but not limited to
             evidence of active cytomegalovirus, active Pneumocystis carinii, aspergillosis, or
             atypical mycobacterial infection, etc, within the previous 6 months.

          -  Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic,
             hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic or cerebral
             disease.

          -  History of lymphoproliferative disease including lymphoma or signs suggestive of
             possible lymphoproliferative disease, such as lymphadenopathy of unusual size or
             location (such as nodes in the posterior triangle of the neck, infraclavicular,
             epitrochlear, or periaortic areas), or splenomegaly.

          -  Any current known malignancy or history of malignancy within the previous 5 years,
             except for squamous or basal cell carcinoma of the skin that have been treated with no
             evidence of recurrence.

          -  Patients with moderate or severe heart failure (New York Heart Association [NYHA]
             class III/IV).

          -  Patients with pre-existing or recent onset of central nervous system demyelinating
             disorders.

          -  Known recent substance abuse (drug or alcohol).

          -  Patients in whom multiple venipunctures are not feasible due to poor tolerability or
             lack of easy access.

          -  Have a known infection with HIV or known active hepatitis B/C infection (including
             associated chronic active hepatitis).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2008</study_first_submitted>
  <study_first_submitted_qc>August 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2008</study_first_posted>
  <results_first_submitted>June 2, 2009</results_first_submitted>
  <results_first_submitted_qc>June 2, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 21, 2009</results_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects showing clinical response at Week 30 of a previous double-blind study of infliximab vs placebo (P04280,NCT00202852) were eligible for this study. A total of 105 subjects were eligible (67 from previous placebo &amp; 38 from previous infliximab group) for this extension study, among whom a total of 92 enrolled to participate in the extension.</recruitment_details>
      <pre_assignment_details>Of the 92 enrolled subjects, 61 were from the placebo group and 31 from the infliximab group of the previous study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Open Label Infliximab + Methotrexate</title>
          <description>Open label Infliximab infusions at weeks 0, 2, and 6 and every 8 weeks + methotrexate (MTX)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57">These participants continued treatment until trial was completed by Sponsor.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Open Label Infliximab + Methotrexate</title>
          <description>Open label Infliximab infusions at weeks 0, 2, and 6 and every 8 weeks + methotrexate (MTX)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="92"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.1" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;30 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 30 and less than 40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 40 and less than 50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 50 and less than 60 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 60 and less than 70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Experiencing Any Adverse Event</title>
        <time_frame>throughout entire study (61 +/- 28.9 weeks on average)</time_frame>
        <population>All participants were included regardless of how long they stayed in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Infliximab + Methotrexate</title>
            <description>Open label Infliximab infusions at weeks 0, 2, and 6 and every 8 weeks + methotrexate (MTX)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Experiencing Any Adverse Event</title>
          <population>All participants were included regardless of how long they stayed in the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Experiencing Serious Adverse Event</title>
        <description>Serious adverse events are defined as death, life-threatening events, persistent or significant disability/incapacity, hospitalization or prolongation of hospitalization and congenital anomalies.</description>
        <time_frame>throughout entire study (61 +/- 28.9 weeks on average)</time_frame>
        <population>All participants were included regardless of how long they stayed in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Infliximab + Methotrexate</title>
            <description>Open label Infliximab infusions at weeks 0, 2, and 6 and every 8 weeks + methotrexate (MTX)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Experiencing Serious Adverse Event</title>
          <description>Serious adverse events are defined as death, life-threatening events, persistent or significant disability/incapacity, hospitalization or prolongation of hospitalization and congenital anomalies.</description>
          <population>All participants were included regardless of how long they stayed in the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Experiencing Any Infection</title>
        <time_frame>throughout entire study (61 +/- 28.9 weeks on average)</time_frame>
        <population>All participants were included regardless of how long they stayed in the study</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Infliximab + Methotrexate</title>
            <description>Open label Infliximab infusions at weeks 0, 2, and 6 and every 8 weeks + methotrexate (MTX)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Experiencing Any Infection</title>
          <population>All participants were included regardless of how long they stayed in the study</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>During conduct of the trial, adverse events were summarized using WHOART dictionary terms. Adverse events were recoded to MedDRA terms for this section of the results display.</desc>
      <group_list>
        <group group_id="E1">
          <title>Open Label Infliximab + Methotrexate</title>
          <description>Open label Infliximab infusions at weeks 0, 2, and 6 and every 8 weeks + methotrexate (MTX)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastric ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>infusion related reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>anaphylactoid reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>chronic sinusitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>pneumonia cryptococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>pyelonephritis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>oropharyngeal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>rhinitis hypertrophic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>urticaria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>chills</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="27" subjects_affected="19" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>dyspnoea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pruritus</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>urticaria</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All proposed publications/presentations by the investigators or their personnel/associates resulting from/relating to this study must be submitted to SP Korea for review and approval before submission for publication/presentation. If the proposed publication/presentation contains patentable subject matter, which, at SP Koreaâs sole discretion, warrants intellectual property protection, SP Korea may delay any publication or presentation for the purpose of pursuing such protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

